Eli Lilly's Retatrutide Shows Major Weight Loss in Phase 3 Trial

Eli Lilly announced that its experimental drug retatrutide achieved substantial weight loss in a Phase 3 clinical trial conducted with obese patients. According to CNBC, participants receiving the highest dose of retatrutide lost an average of 28.

3% of their body weight over the course of 80 weeks. This result highlights the drug's potential as a treatment for obesity, based on the data reported from the trial.